<< Discovery of molecular pathway in brain may reverse cognitive impact of sleep deprivation | FDA warns four companies to stop marketing illegal opioid pain relievers >>
Read in | English | 日本語 | Finnish

Report on the blood products industry in China

Published on October 27, 2009 at 5:24 AM · No Comments

Reportlinker.com announces that a new market research report is available in its catalogue.

Reportlinker Adds China Blood Products Industry Report, 2009

http://www.reportlinker.com/p0155753/Reportlinker-Adds-China-Blood-Products-Industry-Report-2009.html

The blood products industry has a strong ability to withstand risks and immunity to global financial crisis since it is not greatly influenced by periodicity. Owing to large demand gap, strict supervision, high entry barrier and slower supply growth etc in blood products industry, the prices of China's blood products has soared up and corporate profitability also has increased significantly.

China's blood products industry has been in the transition of policy adjustment since 2003. The plasma collection registered approximately 3,100 tons in 2008 due to restrictions from raw materials and the changes in industry policy.

The report makes an in-depth analysis of the status quo of China's blood product industry, points out the gap between Chinese blood products companies and overseas peers, predicts the development trends, and discusses the investment opportunities and risks. In addition, it also focuses on the research of current operation and development trend of China's seven key blood product companies, such as Hualan Biological Engineering Inc.

Comments
The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News-Medical.Net.



  Country flag

biuquote
  • Comment
  • Preview
Loading